Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Nina Anensen, Anne M Øyan, Sjur Huseby, Karl-Henning Kalland, Øystein Bruserud & Bjørn T Gjertsen. (2007) Early gene expression of acute myeloid leukemia in response to chemotherapy. Expert Review of Anticancer Therapy 7:5, pages 741-751.
Read now
Read now
Articles from other publishers (17)
M Rasche, C von Neuhoff, M Dworzak, J-P Bourquin, J Bradtke, G Göhring, G Escherich, G Fleischhack, N Graf, B Gruhn, O A Haas, T Klingebiel, B Kremens, T Lehrnbecher, A von Stackelberg, J Tchinda, Z Zemanova, C Thiede, N von Neuhoff, M Zimmermann, U Creutzig & D Reinhardt. (2017) Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004. Leukemia 31:12, pages 2807-2814.
Crossref
Crossref
Gholamreza Khamisipour, Farhad Jadidi-Niaragh, Abdolreza Sotoodeh Jahromi, Keivan zandi & Mohammad Hojjat-Farsangi. (2016) Mechanisms of tumor cell resistance to the current targeted-therapy agents. Tumor Biology 37:8, pages 10021-10039.
Crossref
Crossref
Caroline Engen, Line Wergeland, Jørn Skavland & Bjørn Gjertsen. (2014) Targeted Therapy of FLT3 in Treatment of AML—Current Status and Future Directions. Journal of Clinical Medicine 3:4, pages 1466-1489.
Crossref
Crossref
Eystein Oveland, Line Wergeland, Randi Hovland, James B. Lorens, Bjørn Tore Gjertsen & Kari E. Fladmark. (2012) Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines. Cell Biology and Toxicology 28:4, pages 201-212.
Crossref
Crossref
Felicitas Thol, Britta Kölking, Frederik Damm, Katarina Reinhardt, Jan‐Henning Klusmann, Dirk Reinhardt, Nils von Neuhoff, Martijn H. Brugman, Brigitte Schlegelberger, Sebastian Suerbaum, Jürgen Krauter, Arnold Ganser & Michael Heuser. (2012)
Next‐generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with
FLT3
‐ITD or
NPM1
mutations
. Genes, Chromosomes and Cancer 51:7, pages 689-695.
Crossref
Crossref
Wolfgang Kern & Susanne Schnittger. 2012. Laboratory Hematology Practice. Laboratory Hematology Practice
220
233
.
Stanley R. McCormick, Matthew J. McCormick, Patricia S. Grutkoski, Gregory S. Ducker, Nilanjana Banerji, Rodney R. Higgins, John R. Mendiola & John J. Reinartz. (2010)
FLT3
Mutations at Diagnosis and Relapse in Acute Myeloid Leukemia: Cytogenetic and Pathologic Correlations, Including Cuplike Blast Morphology
. Archives of Pathology & Laboratory Medicine 134:8, pages 1143-1151.
Crossref
Crossref
Soo-Mee BangJeong Yeal AhnJiyoon ParkSe Hoon ParkJinny ParkEun Kyung ChoDong Bok ShinJae Hoon LeeSoo Jin YooIn Sang JeonYeo-Kyeoung KimHyeoung Joon KimHee-Nam KimIl-Kwon LeeHyoung Jin KangHee Young ShinHyo Seop Ahn. (2008) Low Frequency and Variability of FLT3 Mutations in Korean Patients with Acute Myeloid Leukemia. Journal of Korean Medical Science 23:5, pages 833.
Crossref
Crossref
Wolfgang Kern, Claudia Haferlach, Torsten Haferlach & Susanne Schnittger. (2007) Monitoring of minimal residual disease in acute myeloid leukemia. Cancer 112:1, pages 4-16.
Crossref
Crossref
Anita Ryningen, Camilla Stapnes & Øystein Bruserud. (2007) Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting. Leukemia Research 31:9, pages 1303-1313.
Crossref
Crossref
Björn Steffen, Carsten Müller-Tidow, Joachim Schwäble, Wolfgang E. Berdel & Hubert Serve. (2005) The molecular pathogenesis of acute myeloid leukemia. Critical Reviews in Oncology/Hematology 56:2, pages 195-221.
Crossref
Crossref
Wolfgang Kern, Claudia Schoch, Torsten Haferlach & Susanne Schnittger. (2005) Monitoring of minimal residual disease in acute myeloid leukemia. Critical Reviews in Oncology/Hematology 56:2, pages 283-309.
Crossref
Crossref
Wolfgang Kern & Susanne Schnittger. (2005) Monitoring of minimal residual disease in acute myeloid leukemia Monitorisierung minimaler Resterkrankung bei akuter myeloischer Leukämie. LaboratoriumsMedizin 29:5, pages 343-367.
Crossref
Crossref
Hitoshi Kiyoi, Masamitsu Yanada & Kazutaka Ozekia. (2005) Clinical Significance of FLT3 in Leukemia. International Journal of Hematology 82:2, pages 85-92.
Crossref
Crossref
Jens Tiesmeier, Carsten Müller-Tidow, Annette Westermann, Andreas Czwalinna, Mandy Hoffmann, Jürgen Krauter, Gerhard Heil, Arnold Ganser, Hubert Serve & Walter Verbeek. (2004) Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy. Leukemia Research 28:10, pages 1069-1074.
Crossref
Crossref
Susanne Schnittger, Claudia Schoch, Wolfgang Kern, Wolfgang Hiddemann & Torsten Haferlach. (2004) FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid Leukaemia. Acta Haematologica 112:1-2, pages 68-78.
Crossref
Crossref
Panagiotis D. Kottaridis, Rosemary E. Gale & David C. Linch. (2003) Flt3 mutations and leukaemia. British Journal of Haematology 122:4, pages 523-538.
Crossref
Crossref